Further Product Information

AUTHOR(S):

Stephen D Sayre is a member of Dykema's corporate Finance practice group. He represents generic pharmaceutical companies in transactional matters including joint ventures, mergers and acquisitions, and commercial contracts.

ABSTRACT

This paper provides the generic pharmaceutical executive with a legal roadmap for acquiring pharmaceutical assets. It describes the three main steps to product acquisition, which are as follows: (1) negotiation and execution of a detailed letter of intent; (2) performance of buyer's due diligence; and (3) negotiation and closing of the acquisition agreement. It also explains the relationship among these three steps and why each step is important to the buyer. In discussing each step of the acquisition process, this paper identifies the key considerations and issues for the buyer to help the buyer mitigate the risks inherent in the acquisition of generic pharmaceutical assets.

ABOUT THE JOURNAL Journal of Generic Medicines ISSN: 1741-1343 The Journal of Generic Medicines is guided by its respected Editor Greg Perry (European Generic Medicines Association) and an international Editorial Board of leading practitioners and Association representatives from the generics industry. Journal of Generic Medicines is the major, international business journal written by and for expert analysis, briefings and legal updates on all aspects of business development, regulatory affairs, manufacturing and marketing affecting the generic pharmaceutical industry. Each quarterly issue publishes analyses, briefings and updates which are of direct relevance to practitioners and that meet the highest intellectual standards.